Work

1908P Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)

Year: 2023

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.1138

Authors: M. Smigelski, S. Sudhaman, S. Nagpal, B. Brooks, T. Gerald, R. Sanchez-Mendez, C. Battista, R. Bhanvadia, A. Kazarian, S. Choi, C. Carson, T. Mahmood, E.Z. White, A. ElNaggar, M.C. Liu, M. Metcalf, R.R. McKay, A. Corcoran, V. Margulis, W. Huang

Institutions: NYU Langone Health, New York University, Natera (United States), The University of Texas Southwestern Medical Center, NYU Grossman Long Island School of Medicine, University of California San Diego, UC San Diego Health System, Moores Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, Fonds Wetenschappelijk Onderzoek, KU Leuven, Vlaamse Interuniversitaire Raad, Kom op tegen Kanker, Vlaamse regering, Ipsen, Stand Up To Cancer

OpenAlex ID: W4387826271

FWCI: 0.632

Cites:

Cited by: 4

Related to: 10